Answers are grounded in this paper and cite their sources.
Background Sickle cell trait (SCT) has traditionally been categorized as a benign carrier state; however, isolated reports and case series have nonetheless described rare complications overlapping with those seen in sickle cell disease (HbSS). The strength and consistency of these associations remain incompletely characterized. In this context, public health institutions like the Centers for Disease Control and Prevention (CDC) have emphasized the need to expand research on SCT. Objective To characterize the clinical and hematological profile of HbAS carriers compared with HbAA individuals and to assess carrier status awareness within a Colombian cohort. Methods A descriptive and analytical cross-sectional study was conducted among 400 adult volunteers from the Pacific and Atlantic Afro-descendant regions. Genotypes were confirmed via high-precision liquid chromatography (HPLC) and rs334 SNP sequencing. Clinical data were retrieved through structured interviews and medical record reviews. Hematological parameters and comorbidities were compared between HbAS and HbAA individuals using robust statistical analysis. Results A significant genotype unawareness was identified, with 45.9% (95%CI: 37.3%–54.8%; n = 56/122) of HbAS carriers being uninformed of their status prior to screening. Serious clinical events were documented predominantly in the HbAS group: Osteomyelitis and atypical diaphyseal femoral osteonecrosis occurred only in carriers (3.3% vs. 0.0%, Fisher´s exact p = 0.016). Neurovascular events; showed a higher prevalence in heterozygous individuals (5.7% vs. 0.9%, p = 0.013). The vast majority of HbAS carriers presented at the time of this project, percentage of HbS 36–40%. Regarding hematological parameters, HbAS individuals exhibited lower mean levels of RDW (12.2 ± 0.7% vs. 13.4 ± 1.3%, p = 0.017), platelets (260 ± 56.4 × 10 9 /L vs. 308.2 ± 95.8 × 10 9 /L, p = 0.003), and white blood cell count (6.1 ± 1.5 × 10 9 /L vs. 7.4 ± 1.8 × 10 9 /L, p = 0.026) compared to non-carrier individuals (HbAA). Conclusion These findings suggest that HbAS may not be uniformly benign, as uncommon but clinically notable vaso-occlusive and osteonecrotic events were observed in a minority of carriers, alongside statistically detectable but subclinical hematological differences and a substantial gap in genotype awareness. Given the cross-sectional design and the small number of severe events, these findings should be considered hypothesis-generating rather than confirmatory. Larger longitudinal studies are needed to clarify their clinical significance and to inform screening and monitoring strategies in high-prevalence populations.
No takes yet. Share an insight, caveat, or question.
Márquez-Benítez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: